What did your March P/L look like: My portfolio faced a downturn in March, particularly with EV stocks, resulting in an unfavorable profit/loss scenario. Pleasant surprises: Did any unexpected trades pay off? Despite this setback, I experienced a pleasant surprise as an unconventional venture into a biotech stock$傑龍(GERN.US)$which yielded modest returns, amidst the market chaos. Next steps for April: What's your plan? Looking ahead to April, I am adopting a Dollar-Cost Av...
Wedbush analysts predict a June approval for the drug, citing 'robust commercial potential.' Stifel analysts concur, estimating a 95% success rate. They foresee discussions shifting to labeling, launch kinetics, and strategic interest, particularly regarding imetelstat's potential exclusivity runway.
Despite the FDA's concerns about the drug's efficacy and safety, Wedbush analyst Robert Driscoll maintains an Outperform rating on Geron, criticizing the FDA's analyses as 'one-sided and misguided'.
傑龍股票討論區
ALLR - RENT - ADIL ) 👈 NO SHORT NO WIN 🤩🤩🤩💰🤩🤗😋
My portfolio faced a downturn in March, particularly with EV stocks, resulting in an unfavorable profit/loss scenario.
Pleasant surprises: Did any unexpected trades pay off?
Despite this setback, I experienced a pleasant surprise as an unconventional venture into a biotech stock $傑龍(GERN.US)$ which yielded modest returns, amidst the market chaos.
Next steps for April: What's your plan?
Looking ahead to April, I am adopting a Dollar-Cost Av...
A quick recap for the weekend ending March 17, 2024.
暫無評論